RT Journal Article
SR Electronic
T1 The Adjunctive Effect of Nebulized Furosemide in Acute Treatment of Patients with Chronic Obstructive Pulmonary Disease Exacerbation: A Randomized Controlled Clinical Trial
JF Respiratory Care
FD American Association for Respiratory Care
SP respcare.02160
DO 10.4187/respcare.02160
A1 Hojat Sheikh Motahar Vahedi
A1 Babak Mahshidfar
A1 Helaleh Rabiee
A1 Soheil Saadat
A1 Hamid Shokoohi
A1 Mojtaba Chardoli
A1 Vafa Rahimi-Movaghar
YR 2013
UL http://rc.rcjournal.com/content/early/2013/04/30/respcare.02160.abstract
AB Objective: To examine the effect of nebulized furosemide as an adjunct to the conventional treatment of patients with chronic obstructive pulmonary disease (COPD) exacerbation in an emergency department. Method: In this randomized double-blinded clinical trial, patients with the clinical presentation of COPD exacerbation were randomized to receive 40 mg nebulized furosemide (intervention group) or placebo (control group) as an adjunct to their conventional treatments. Changes in the severity of dyspnea (dyspnea-Visual Analog Scale), Forced Expiratory Volume in one second (FEV1), arterial blood gas (ABG) measurements, blood pressure, pulse rate and respiratory rate were assessed at the baseline and compared in the two groups, one hour after the treatment. Result: One hundred COPD patients with the mean age of 73.1± 8.7 were randomized. Clinical parameters including the severity of dyspnea and FEV1 improved significantly after both therapies, whereas higher FEV1 and lower severity of dyspnea were observed in the furosemide group compared to the placebo group (p<0.001). In addition, patients treated with nebulized furosemide yielded a significant elevation in the mean pH and Pao2 an hour after the treatment (p<0.001). There was a significant decrease in the mean blood pressure and pulse rate in the furosemide group compared with the placebo. Conclusion: Nebulized furosemide as an adjunctive to the conventional treatment demonstrated additional clinical benefits for acute management of patients with COPD exacerbation. This may provide an additional therapeutic option in treatment of patients with COPD exacerbation.